BR0314053A - Pirazolopiridinas e métodos de obtenção e uso das mesmas - Google Patents

Pirazolopiridinas e métodos de obtenção e uso das mesmas

Info

Publication number
BR0314053A
BR0314053A BR0314053-9A BR0314053A BR0314053A BR 0314053 A BR0314053 A BR 0314053A BR 0314053 A BR0314053 A BR 0314053A BR 0314053 A BR0314053 A BR 0314053A
Authority
BR
Brazil
Prior art keywords
obtaining
methods
pyrazolopyridines
formula
pirazolopyridines
Prior art date
Application number
BR0314053-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Wen-Cherng Lee
Mary Beth Carter
Lihong Sun
Paul Lyne
Claudio Chuaqui
Zhongli Zheng
Juswinder Singh
Paula Boriack-Sjodin
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of BR0314053A publication Critical patent/BR0314053A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR0314053-9A 2002-09-06 2003-09-05 Pirazolopiridinas e métodos de obtenção e uso das mesmas BR0314053A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40881102P 2002-09-06 2002-09-06
PCT/US2003/027722 WO2004022054A1 (en) 2002-09-06 2003-09-05 Pyrazolopyridines and methods of making and using the same

Publications (1)

Publication Number Publication Date
BR0314053A true BR0314053A (pt) 2005-07-19

Family

ID=31978684

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314053-9A BR0314053A (pt) 2002-09-06 2003-09-05 Pirazolopiridinas e métodos de obtenção e uso das mesmas

Country Status (20)

Country Link
US (1) US7691865B2 (https=)
EP (1) EP1551398A4 (https=)
JP (1) JP2006502165A (https=)
KR (1) KR20050057235A (https=)
CN (1) CN1694698A (https=)
AR (1) AR041207A1 (https=)
AU (1) AU2003268447B2 (https=)
BR (1) BR0314053A (https=)
CA (1) CA2497970A1 (https=)
EA (1) EA009441B1 (https=)
GE (1) GEP20074125B (https=)
IS (2) IS7726A (https=)
MX (1) MXPA05002443A (https=)
NO (1) NO20051503D0 (https=)
NZ (1) NZ539069A (https=)
PL (1) PL375699A1 (https=)
RS (1) RS20050200A (https=)
UA (1) UA80295C2 (https=)
WO (1) WO2004022054A1 (https=)
ZA (1) ZA200501856B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
JP4931589B2 (ja) * 2004-07-02 2012-05-16 正明 松岡 ＴＧＦβ２を標的としたアルツハイマー病治療薬のスクリーニング法
AU2005295734A1 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
EP1873157A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
MX2009003518A (es) 2006-10-03 2009-08-25 Genzyme Corp Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
JP2010540451A (ja) * 2007-09-20 2010-12-24 ワイス・エルエルシー ピラゾロ［５，１−ｃ］［１，２，４］トリアジン、その調製法および使用法
RU2487131C2 (ru) * 2008-03-14 2013-07-10 Оцука Фармасьютикал Ко., Лтд. Ингибитор ммр-2 и/или ммр-9
CN101544634B (zh) * 2008-03-27 2011-08-10 天津药物研究院 2-苯基-3-取代吡唑并[1,5-a]吡啶类衍生物及其制备方法和用途
EP2402335A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402344A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
BR112016005199B1 (pt) 2013-08-23 2022-02-22 Neupharma, Inc Certos compostos químicos, composições, e métodos
WO2015097121A1 (en) 2013-12-23 2015-07-02 Norgine B.V. Compounds useful as ccr9 modulators
US10342795B2 (en) * 2014-03-27 2019-07-09 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors
WO2018035061A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020231990A1 (en) 2019-05-13 2020-11-19 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof
JP2023509760A (ja) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド Ａｌｋ５阻害剤複合体およびその使用
CN112707902B (zh) * 2020-03-23 2022-04-15 杭州阿诺生物医药科技有限公司 TGF-β受体抑制剂
CN114380818B (zh) * 2020-10-16 2026-04-10 四川科伦博泰生物医药股份有限公司 吡唑并吡啶类化合物，及其药物组合物、制备方法和用途
CN121712526A (zh) 2023-06-13 2026-03-20 辛瑟斯治疗股份有限公司 抗cd5抗体及其用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940486A (en) 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4302464A (en) 1980-10-16 1981-11-24 Pfizer Inc. Imidazolylpyridine therapeutic agents
US4686231A (en) 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
JP2753659B2 (ja) * 1990-09-03 1998-05-20 株式会社大塚製薬工場 ピラゾール誘導体
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
GB9423460D0 (en) 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
WO1997001575A1 (en) 1995-06-29 1997-01-16 Fujisawa Pharmaceutical Co., Ltd. Substance wf16616, process for production thereof, and use thereof
US5837719A (en) 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5792778A (en) 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6083949A (en) 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
ZA9610687B (en) 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
PL187516B1 (pl) 1996-01-11 2004-07-30 Smithkline Beecham Corp Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki
US6046208A (en) 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
JP2000504013A (ja) 1996-02-01 2000-04-04 スミスクライン・ビーチャム・コーポレイション エンドセリンレセプターアンタゴニスト
US6372741B1 (en) 1996-03-08 2002-04-16 Smithkline Beecham Corporation Use of CSAID™ compounds as inhibitors of angiogenesis
US6096748A (en) 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
EP0889888A4 (en) 1996-03-25 2003-01-08 Smithkline Beecham Corp NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
EP0889887A4 (en) 1996-03-25 2003-06-11 Smithkline Beecham Corp TREATMENT OF CENTRAL NERVOUS SYSTEM INJURIES
US5939557A (en) 1996-04-03 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5854265A (en) 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5880140A (en) 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5872136A (en) 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
ES2239357T3 (es) 1996-06-10 2005-09-16 MERCK & CO., INC. Imidazoles sustituidos que tienen actividad inhibidora de citoquinas.
US5854264A (en) 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
KR20000057137A (ko) 1996-11-19 2000-09-15 스티븐 엠. 오드레 아릴 및 헤테로아릴로 치환된 융합 피롤 항염증제
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US5939439A (en) 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5965583A (en) 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
US6087496A (en) 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
EP1019394A1 (en) 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
IL132736A0 (en) 1997-05-22 2001-03-19 Searle & Co 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
DE69835518T2 (de) 1997-06-12 2007-08-09 Aventis Pharma Ltd., West Malling Imidazolyl-cyclische acetale
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
AU8757098A (en) 1997-06-30 1999-02-10 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
AU1924699A (en) 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
CA2341370A1 (en) 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
DE69914357T2 (de) 1998-11-04 2004-11-11 Smithkline Beecham Corp. Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
US6288089B1 (en) 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
KR100711538B1 (ko) 1998-12-25 2007-04-27 아스카 세이야쿠 가부시키가이샤 아미노피라졸 유도체
EP1175419B1 (en) 1999-04-02 2003-05-28 Bristol-Myers Squibb Pharma Company Aryl sulfonyls as factor xa inhibitors
DE60001229T2 (de) 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia Triarylimidazole
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
DE60020560T2 (de) 1999-06-03 2006-04-27 Teikoku Hormone Mfg. Co., Ltd. Substituierte pyrazol-derivate
ES2260033T3 (es) 1999-07-02 2006-11-01 Stuart A. Lipton Uso de los inhibidores p38 mapk en efermadades oftalmicas.
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US20030109428A1 (en) 1999-12-01 2003-06-12 John Bertin Novel molecules of the card-related protein family and uses thereof
CO5271715A1 (es) 1999-12-21 2003-04-30 Sugen Inc 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
ATE266022T1 (de) 2000-03-06 2004-05-15 Smithkline Beecham Plc Imidazol derivate als raf kinase inhibitoren
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
JP4722318B2 (ja) * 2000-06-05 2011-07-13 ローム株式会社 チップ抵抗器
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
WO2001091749A1 (en) 2000-06-01 2001-12-06 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
WO2002000647A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7199137B2 (en) 2000-09-21 2007-04-03 Smithkline Beecham Plc Imidazole derivatives as Raf kinase inhibitors
ATE297392T1 (de) 2000-10-18 2005-06-15 Ortho Mcneil Pharm Inc Substituierte imidazole, die sich für die behandlung entzündlicher krankheiten eignen
US6630325B1 (en) 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
US6603005B2 (en) 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
AU2002225730A1 (en) 2000-11-16 2002-05-27 Smith Kline Beecham Corporation Compounds
ATE365730T1 (de) 2000-11-20 2007-07-15 Smithkline Beecham Corp Neuartige verbindungen
ATE375345T1 (de) * 2000-12-28 2007-10-15 Ono Pharmaceutical Co Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-verbindun als crf-rezeptor antagonist
ATE291020T1 (de) 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
JP2004521901A (ja) * 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
CA2445568A1 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
GB0127433D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
JP2005516916A (ja) 2001-12-11 2005-06-09 スミスクライン ビーチャム コーポレーション 抗ヘルペス薬としてのピラゾロ−ピリジン誘導体
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
EP1543001B1 (en) * 2002-09-17 2007-08-15 Eli Lilly And Company Pyrazolopyridine derivatives as tgf beta signal transduction inhibitors for the treatment of cancer
MXPA05002981A (es) 2002-09-18 2005-06-22 Pfizer Prod Inc Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf).
AU2003256003A1 (en) 2002-09-18 2004-04-08 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors
AU2003300099A1 (en) 2003-01-02 2004-07-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
ZA200602755B (en) 2003-09-06 2007-06-27 Vertex Pharma Modulators of ATP-binding cassette transporters

Also Published As

Publication number Publication date
IS7726A (is) 2005-03-04
MXPA05002443A (es) 2005-09-30
US7691865B2 (en) 2010-04-06
AU2003268447B2 (en) 2008-07-24
EP1551398A1 (en) 2005-07-13
NO20051503L (no) 2005-03-21
PL375699A1 (en) 2005-12-12
NO20051503D0 (no) 2005-03-21
AR041207A1 (es) 2005-05-11
EA009441B1 (ru) 2007-12-28
KR20050057235A (ko) 2005-06-16
AU2003268447A1 (en) 2004-03-29
GEP20074125B (en) 2007-06-11
UA80295C2 (en) 2007-09-10
JP2006502165A (ja) 2006-01-19
EP1551398A4 (en) 2006-06-07
EA200500450A1 (ru) 2005-08-25
CN1694698A (zh) 2005-11-09
CA2497970A1 (en) 2004-03-18
RS20050200A (sr) 2007-08-03
ZA200501856B (en) 2006-04-26
NZ539069A (en) 2007-03-30
IS7725A (is) 2005-03-04
WO2004022054A1 (en) 2004-03-18
US20060106033A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
BR0314053A (pt) Pirazolopiridinas e métodos de obtenção e uso das mesmas
BRPI0407454A (pt) Pirazóis e métodos de preparar e usar os mesmos
BR0314052A (pt) Imidazolpiridinas e métodos para sua fabricação e uso
EA200401309A1 (ru) Тризамещённые гетероарилы и способы их получения и применения
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BR0316296A (pt) Compostos lapacone e seus métodos de uso
WO2005012530A3 (en) Antagonists and agonists of ldcam and methods of use
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
BR0313233A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, e, composição farmacêutica
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
NO20043013L (no) Tetrahydrokinolin analoger som muskarine agonister
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
CY1105080T1 (el) Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης
BR0206985A (pt) Anticorpos modificados e métodos de uso
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
WO2004096148A3 (en) Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
BRPI0412893A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 31/415, A61K 31/445, A61P 29/00, A61P 35/00

Ipc: A61K 31/415 (2011.01), A61K 31/445 (2011.01), A61P

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.